Cartesian Therapeutics Inc (RNAC) USD0.0001

Sell:$18.50Buy:$22.18$1.09 (5.48%)

Prices delayed by at least 15 minutes
Sell:$18.50
Buy:$22.18
Change:$1.09 (5.48%)
Prices delayed by at least 15 minutes
Sell:$18.50
Buy:$22.18
Change:$1.09 (5.48%)
Prices delayed by at least 15 minutes

Company Information

About this company

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Key people

Carsten Brunn
President, Chief Executive Officer, Director
Blaine Davis
Chief Financial Officer
Emily English
Senior Vice President, Head of Manufacturing Operations
Metin Kurtoglu
Chief Technology Officer
Chris Jewell
Chief Scientific Officer
Milos Miljkovic
Chief Medical Officer
Carrie S. Cox
Independent Chairman of the Board
Murat Kalayoglu
Director
Kemal Malik
Director
Michael Singer
Director
Timothy C. Barabe
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8162123025
  • Market cap
    $505.50m
  • Employees
    38
  • Shares in issue
    25.41m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.